In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice
Authors:
- Zahid Rafiq BhatZBZahid Rafiq Bhat
- Manvendra KumarMKManvendra Kumar
- Nisha SharmaNSNisha Sharma
- Umesh Prasad YadavUYUmesh Prasad Yadav
- Tashvinder SinghTSTashvinder Singh
- Gaurav JoshiGJGaurav Joshi
- Brahmam PujalaBPBrahmam Pujala
- Mohd RajaMRMohd Raja
- Joydeep ChatterjeeJCJoydeep Chatterjee
- Kulbhushan TikooKTKulbhushan Tikoo
- Sandeep SinghSSSandeep Singh
- Raj KumarRKRaj Kumar
Open Access
Abstract
Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a non-covalent imidazo[1,2-a]quinoxaline-based EGFR inhibitor (6b), which showed promising inhibitory activity against the gefitinib-resistant H1975(L858R/T790M) lung cancer cell line. In the present study, we further explored the 6b compound in vivo by employing the A549-induced xenograft model in nude mice. The results indicate that the administration of the 6b compound significantly abolished the growth of the tumor in the A549 xenograft nude mice. Whereas the control mice bearing tumors displayed a declining trend in the survival curve, treatment with the 6b compound improved the survival profile of mice. Moreover, the histological examination showed the cancer cell cytotoxicity of the 6b compound was characterized by cytoplasmic destruction observed in the stained section of the tumor tissues of treated mice. The immunoblotting and qPCR results further signified that 6b inhibited EGFR in tissue samples and consequently altered the downstream pathways mediated by EGFR, leading to a reduction in cancer growth. Therefore, the in vivo findings were in corroboration with the in vitro results, suggesting that 6b possessed potential anticancer activity against EGFR-dependent lung cancer. 6b also exhibited good stability in human and mouse liver microsomes.Keywords
Funding Information
- Anusandhan National Research Foundation (EMR/2017/002702, 02(0397)/21/EMR-II)
- CSIR (EMR/2017/002702, 02(0397)/21/EMR-II)
This publication has 47 references indexed in Scilit:
- Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A ReviewOncology Research and Treatment, 2013
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathwayOncogene, 2009
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFRCancer Research, 2009
- Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patientsBreast Cancer Research, 2008
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase InhibitorsClinical Cancer Research, 2006
- Epidermal growth factor receptor (EGFR) signaling in cancerGene, 2006
- Time-and concentration-dependent penetration of doxorubicin in prostate tumorsAAPS PharmSci, 2001
- Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapyDrugs of the Future, 2001